Browsing by Author "Unsal, Oktay"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Publication Clinical and laboratory outcomes of the solid cancer patients reinfected with sars-cov-2(Future Medicine, 2021-11-26) Unsal, Oktay; Yazici, Ozan; Ozdemir, Nuriye; Uner, Aytug; Ozet, Ahmet; Cubukcu, Erdem; ÇUBUKÇU, ERDEM; Ocak, Birol; OCAK, BİROL; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; 0000-0001-7537-1699; 0000-0001-8731-9636; AEC-2238-2022Lay abstract Solid cancer patients are at a higher risk than general population in terms of Coronavirus disease 2019 (COVID-19) infectivity and COVID-19-associated death and disease. It is also known that COVID-19 infection has a more severe course in immunocompromised patients. Solid cancer patients may be a vulnerable subgroup of patients to reinfection with COVID-19. The rate of reinfection was 3.1% (n = 32) in our study population of 1024 solid cancer patients who were tested positive on a COVID-19 PCR test. The death rate of the patients with solid cancer was 34.3% (n = 11). In addition, we demonstrated that intensive care follow-up is significantly longer during the reinfection period. It was demonstrated that the time between the last dose of chemotherapy for the patients and the reinfection COVID PCR positivity did not affect the death rate. The COVID-19 pandemic has affected people's daily lives and treatments in many aspects. Owing to the high death rate of reinfection, even if cancer patients have reinfection, our approach is to continue cancer treatment as soon as the patient is cured. Finally, we support the priority vaccination of cancer patients.Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test and those with improved clinical conditions after infection with COVID-19 were enrolled in this study. Patients who received a positive COVID-19 PCR test 28 days after the initial positive PCR test were considered as reinfected. Results: A total of 1024 patients with the diagnosis of solid malignancy and COVID-19 PCR positivity were examined. The reinfection rate was 3.1%. Mortality rate of reinfection was 34.3%. The serum ferritin and creatinine values in reinfection were found to be significantly higher than the first infection (respectively; p = 0.015, p = 0.014). Conclusion: This study has demonstrated one of the first preliminary clinical results of COVID-19 reinfection in solid cancer patients.Publication Demographic, clinical and laboratory characteristics of adult-onset minimal change disease in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group(Springer, 2022-09-30) Aydin, Zeki; Yilmaz, Murvet; Sipahioglu, Murat; Dervisoglu, Erkan; Aydemir, Nihal; Uzun, Sami; Istemihan, Zulal; Unsal, Oktay; Tatar, Erhan; Berktas, Haci Bayram; Ozdemir, Arzu; Sumnu, Abdullah; Kumru, Gizem; Cetinkaya, Hakki; Kazan, Sinan; Kocyigit, Ismail; Gokalp, Cenk; Hasbal, Baris; Artan, Ayse Serra; Ozelsancak, Ruya; Taymez, Dilek; Yadigar, Serap; Alagoz, Selma; Aslan, Bilal Burcak; Yaylaci, Selcuk; Jabrayilov, Jabrayil; Turgutalp, Kenan; Dursun, Belda; Sahin, Garip; Ünsal, Oktay; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Nefroloji Bilim Dalı.; JJK-9214-2023Purpose In our study, diagnostic and demographic characteristics of patients diagnosed with minimal change disease (MCD) by biopsy, clinical and laboratory findings in our country were investigated. Methods Data were obtained from the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group database. Demographic characteristics, indications for biopsy, diagnosis of the glomerular diseases, comorbidities, laboratory and biopsy findings of all patients were recorded. The data presented are cross-sectional and includes application data for the biopsy period. Results Of 3875 patients, 233 patients with MCD (median age 35.0 years) were included in the study, which constitutes 6.0% of the total glomerulonephritis database. Renal biopsy was performed in 196 (84.1%) patients due to nephrotic syndrome. Median serum creatinine was 0.7 (0.6-1.0) mg/dl, mean eGFR was 104 +/- 33 ml/min/1.73 m(2) and median proteinuria 6000 mg/day. The number of patients under the age of 40 years was 139 (59.7%) (Group A), and the number of patients aged 40 years and over was 94 (40.3%) (Group B). Compared to Group A, global sclerotic glomeruli (24 vs. 43, p < 0.001) interstitial inflammation (15 vs. 34, p < 0.001), interstitial fibrosis (20 vs. 31, p = 0.001, vascular changes (10 vs. 25, p < 0.001) and tubular atrophy (18 vs. 30, p < 0.001) were found to be significantly higher in Group B. There was no difference in immunofluorescent staining properties between the two groups. Conclusion Our data are generally compatible with the literature. Chronic histopathological changes were more common in patients aged 40 years and older than younger patients. Studies investigating the effects of these different features on renal survival are needed.Publication Evaluation of one year, five years and ten years life time of patients with kidney transplant: Single-center experience(Lippincott Williams & Wilkins, 2020-09-01) Elgin, Ersin; Aydın, Mehmet Fethullah; Ünsal, Oktay; Yıldız, Abdulmecid; Oruç, Ayşegül; Günseren, Kadir Ömur; Çiçek, Mehmet Çağatay; Budak, Ferah; Oral, H. Barbaros; Ersoy, Alparlan; Elgin, Ersin; Aydın, Mehmet Fethullah; Unsal, Oktay; Yıldız, Abdulmecid; ORUÇ, AYŞEGÜL; GÜNSEREN, KADİR ÖMÜR; ÇİÇEK, MEHMET ÇAĞATAY; BUDAK, FERAH; ORAL, HALUK BARBAROS; Ersoy, Alparlan; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Bursa Bölge Koordinasyon Merkezi.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; 0000-0002-9509-5799; 0000-0002-5665-7402; 0000-0002-0342-9692; 0000-0001-7625-9148; 0000-0003-0463-6818; F-4657-2014; K-7285-2012; AAH-4002-2021; AAJ-8220-2020; IZP-9398-2023; DXA-2790-2022; JKA-8956-2023; JJY-8484-2023; EIF-8983-2022; JJO-6552-2023; CNT-9025-2022